Pharma Superintelligence: ALS Drug Repurposing and Multimodal AI Drug Discovery

Insilico Medicine is pursuing 'pharmaceutical superintelligence' - using AI to transform the drug discovery process. The company recently launched its MMAI Gym that aims to train generalist large language models like ChatGPT and Gemini to perform as well as specialist models for drug discovery tasks. Insilico's platform ingests biological, chemical, and clinical data to generate hypotheses about disease targets and candidate molecules. By automating steps that once required legions of chemists and biologists, Insilico says it can sift through vast design spaces, nominate high-quality therapeutic candidates, and even repurpose existing drugs. The company recently used its AI models to identify whether existing drugs could be repurposed to treat ALS. Insilico's automated labs generate multi-layer biological data from disease samples at scale without human intervention. The company is also building digital twins of humans to run virtual clinical trials.